Cantor Fitzgerald Reaffirms “Overweight” Rating for MiMedx Group (NASDAQ:MDXG)

Cantor Fitzgerald restated their overweight rating on shares of MiMedx Group (NASDAQ:MDXG) in a research report report published on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $11.00 price objective on the stock. Cantor Fitzgerald also issued estimates for MiMedx Group’s FY2024 earnings at $0.29 EPS.

Other analysts have also issued research reports about the stock. HC Wainwright reaffirmed a buy rating and set a $11.00 price target on shares of MiMedx Group in a research report on Wednesday, May 1st. StockNews.com raised shares of MiMedx Group from a buy rating to a strong-buy rating in a research report on Thursday, July 11th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of Buy and a consensus target price of $12.00.

MiMedx Group Stock Down 3.3 %

MDXG stock opened at $6.46 on Thursday. The firm has a market cap of $953.52 million, a PE ratio of 14.68 and a beta of 1.98. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.71 and a current ratio of 3.85. The firm’s 50 day moving average price is $7.09 and its 200-day moving average price is $7.43. MiMedx Group has a one year low of $5.57 and a one year high of $9.27.

Institutional Trading of MiMedx Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AJOVista LLC purchased a new stake in MiMedx Group in the fourth quarter valued at approximately $25,000. Headlands Technologies LLC purchased a new stake in MiMedx Group in the first quarter valued at approximately $27,000. Entropy Technologies LP acquired a new position in shares of MiMedx Group in the first quarter worth $99,000. Loudon Investment Management LLC acquired a new position in shares of MiMedx Group in the fourth quarter worth $105,000. Finally, Shell Asset Management Co. acquired a new position in shares of MiMedx Group in the first quarter worth $113,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.